Meet Trevena: Pain relief drug seen having fewer adverse effects
In an exclusive interview with The Fly, Trevena's (TRVN) CEO Maxine Gowen discussed the company's Oliceridine's market opportunity and how it distinguishes itself from conventional opioids analgesics for the treatment of moderate to severe acute pain: "Oliceridine was designed specifically based on Nobel Prize winning scientific insights to try to overcome the opioid related adverse events that you see with conventional opioids. And this is incredibly important because more than fifty million patients in the U.S. are treated with an IV opioid in the hospital every year and dealing with these adverse effects can very much complicate treatment and also really impact patient safety. The innovation behind Oliceridine is that through its mechanism of action, it leverages the benefits of conventional opioids like morphine. It has the ability of delivering unparalleled pain relief, while reducing the associated nausea and vomiting, and the slowed breathing that can ultimately lead to respiratory depression and in worst case death. Our clinical data so far has shown that Oliceridine can deliver a very rapid pain relief at similar levels to morphine, but with fewer accompanying adverse events. That's what we call the widest therapeutic window, which is the margin between an effective dose and a dose which has a safety or a tolerability problem. And we really think that this should improve hospital care for patients and make it easier for physicians to treat those patients effectively." "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.